(Q36360540)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16393277%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

review article

1 reference

title

Systematic review: coxibs, non-steroidal anti-inflammatory drugs or no cyclooxygenase inhibitors in gastroenterological high-risk patients? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16393277%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16393277%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Mark A Ainsworth

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16393277%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

author name string

Csillag C

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16393277%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Rask-Madsen J

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16393277%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

language of work or name

English

0 references

publication date

1 January 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16393277%20AND%20SRC:MED&resulttype=core&format=json

Alimentary Pharmacology & Therapeutics

15 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16393277%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16393277%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16393277%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

page(s)

27-33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16393277%20AND%20SRC:MED&resulttype=core&format=json

Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum?

15 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02745.X

Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02745.X

21 January 2018

Cyclooxygenases 1 and 2

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02745.X

Emergency admissions for upper gastrointestinal disease and their relation to NSAID use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02745.X

Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02745.X

COX-2 and beyond: Approaches to prostaglandin inhibition in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02745.X

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02745.X

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02745.X

The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02745.X

Efficacy and safety of valdecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02745.X

Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02745.X

Valdecoxib-associated acute generalized exanthematous pustulosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02745.X

The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02745.X

Etoricoxib reduced pain and disability and improved quality of life in patients with chronic low back pain: a 3 month, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02745.X

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02745.X

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02745.X

Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02745.X

Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02745.X

Impact of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on gastric ulcerogenesis in experimental animals and in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02745.X

Nonsteroidal anti-inflammatory drug gastropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02745.X

Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02745.X

A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02745.X

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02745.X

Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02745.X

Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02745.X

Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02745.X